An interventional study of Low load blood flow restriction resistance training and Low load resistance training without Blood Flow Restriction in Colorectal Cancer Survivors, sponsored by Ahmed Adel Ahmed Elsayed Ali Radwan. Recruiting at 1 site in Egypt. Open to participants aged 40 Years to 59 Years. Per ClinicalTrials.gov, last updated 2026-10-21.
Sponsored by Ahmed Adel Ahmed Elsayed Ali Radwan · Not applicable, Interventional, and Treatment
Among 54 studies in Colorectal Neoplasms with a site in Egypt — 15 open to participants now, 16 under way, 5 of them phase 3. Colorectal Neoplasms · Egypt.
Among the 54 studies in Colorectal Neoplasms with a site in Egypt, this one is the 17th largest by planned enrollment of the 31 interventional ones that give a count, is one of 5 that started in 2026, is one of 11 with no phase, reaches primary completion later than 12 of the 15 other live ones, and was the 53rd registered.
6,541 studies on the registry are indexed under Colorectal Neoplasms; 1,667 are open to participants now.
Browse Colorectal Neoplasms studies →15 of the 54 studies in Colorectal Neoplasms with a site in Egypt are open now. Recruiting first, the newest first:
Ain Shams University · Sites in Egypt
Minia University · Sites in Egypt
Sohag University · Sites in Egypt
Sohag University · Sites in Egypt
toqa saad mohammed mohammed · Sites in Egypt
A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →
Of the 1,185 Colorectal Neoplasms studies recruiting now, 769 (65%) set no upper age limit and 265 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 40 Years to 59 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 7 · Phase 3 13 · Phase 4 1
First in 1999; this study’s year is marked. 5 started in 2026.
This study's planned enrollment of 54 is below the median of 76 across 4,800 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 60 across the 31 interventional studies, 93 across the 22 observational. Of the 29 that completed or were terminated, 2 (7%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 54 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Ahmed Adel Ahmed Elsayed Ali Radwan as lead sponsor.
Ahmed Adel Ahmed Elsayed Ali Radwan has 1 study filed under Colorectal Neoplasms — fewer than ten, so there is no comparison to draw.
5 of the studies in Colorectal Neoplasms with a site in Egypt that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07736495Phase 3Ain Shams UniversityProtective Role of Alpha-Lipoic Acid in Chemotherapy-Induced Mucositis | 2026-12-27 |
| NCT07922642Alexandria UniversityNurse-Led Prehabilitation Before Major Abdominal Cancer Surgery | 2027-02-05 |
| NCT07144683Minia UniversityAnastomotic Leakage After Colorectal Surgery. | 2027-03-25 |
| NCT07874035Ahmed Adel Ahmed Elsayed Ali RadwanLow Load Blood Flow Restriction Resistance Training in Colorectal Cancer Related Sarcopenia | 2027-08-15 |
| NCT07215936Sohag UniversityDose-dense Capecitabine Schedule [7days on _7 Days Off] in Colorectal Cancer in Comparison With Standered Regimen | 2027-09 |
Among the 54 studies in Colorectal Neoplasms with a site in Egypt, from their registry updates:
This tab as a report to print or save as PDF → With an account.
PURPOSE:
To investigate the effects of low-load resistance training combined with blood flow restriction on muscle strength, functional performance, and cancer-related fatigue in colorectal cancer survivors with probable sarcopenia.
BACKGROUND:
Muscle weakness and cancer-related fatigue are prevalent in colorectal cancer survivors with probable sarcopenia and are associated with adverse outcomes. High-load resistance training is often poorly tolerated in this population. Although low-load resistance training with blood flow restriction shows promise, colorectal cancer-specific randomized evidence remains limited.
HYPOTHESES:
It is hypothesized that low-load blood flow restriction resistance training will lead to significant improvements in muscle strength and functional performance and a significant reduction in cancer-related fatigue in colorectal cancer survivors with probable sarcopenia.
RESEARCH QUESTION:
Does low-load blood flow restriction resistance training lead to significant improvements in muscle strength and functional performance and a significant reduction in cancer-related fatigue in colorectal cancer survivors with probable sarcopenia?
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Behavioral: Low load blood flow restriction resistance training
Behavioral: Low load resistance training without Blood Flow Restriction
Low-load resistance training combined with blood flow restriction using pneumatic cuffs applied to the proximal lower limb at 60% arterial occlusion pressure. Resistance exercise is performed at 30% of one-repetition maximum (1RM), using 30-15-15-15 repetitions with 30-60 seconds of rest between sets. The intervention is supervised twice weekly for 12 weeks.
Low-load resistance training without blood flow restriction. Resistance exercise is performed at 30% of one-repetition maximum (1RM), using 30-15-15-15 repetitions with 30-60 seconds of rest between sets. The intervention is supervised twice weekly for 12 weeks.
Change in Lower Limb Muscle Strength
Lower limb muscle strength will be measured using a calibrated digital force gauge. Muscle strength will be assessed at baseline before the intervention and after completion of the 12 weeks intervention.
Time frame: Baseline (Week 0) and immediately after completion of the 12-week intervention (Week 12).
Change in Functional Lower Limb Performance
Functional lower limb performance will be assessed using the 30-Second Sit-to-Stand Test at baseline and after completion of the 12-week intervention.
Time frame: Baseline (Week 0) and immediately after completion of the 12-week intervention (Week 12).
Change in Cancer Related Fatigue
Cancer-related fatigue will be assessed using the 13-item Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) scale at baseline and immediately after completion of the 12-week intervention. The FACIT-F fatigue subscale ranges from 0 to 52, with higher scores indicating less fatigue and better quality of life.
Time frame: Baseline (Week 0) and immediately after completion of the 12-week intervention (Week 12).
Started May 2026 (actual). Primary completion is estimated for Aug 2027, 14 months after the start.
Of 898 non-industry interventional studies with no phase under Colorectal Neoplasms, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 62. This study's planned 14 months is below that.
Counting every sponsor, half of 955 studies reached it within 32 months; a quarter within 14 and three quarters within 60.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.